The Lonza Viral team has extensive cGMP experience in developing viral vaccine and viral gene therapy products, dating back to 1996. Lonza Viral can produce GMP batches of adenoviral, AAV, lentiviral vectors, and attenuated adenovirus products in both adherent and suspension cell lines. With the construction and validation of its second cGMP clean room in 2012, Lonza Viral is able to support large-scale production up to 2,000 liters.
Our team has expertise in downstream processing for a wide range of products. We have multiple purification skids to accommodate our client’s product purification needs at different scales. The Lonza Viral team has produced and released over 60 GMP batches of products for use in multiple clinical trials worldwide including two Phase III clinical trials. We have experience in designing and documenting processes that ensure a successful product development experience for your organization.
We offer the following services for adenoviral, AAV, and lentiviral vectors, replication-competent adenovirus, and viral vaccines:
- cGMP virus banking and characterization
- cGMP cell banking and characterization
- Adherent and suspension cells
- Large scale ultra/diafiltration
- Depth filtration
- Chromatographic purification
- Aseptic Fill/Finish